{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.259","upperLimit":"0.693","value":"0.495"},{"groupId":"OG001","lowerLimit":"0.419","upperLimit":"0.847","value":"0.683"},{"groupId":"OG002","lowerLimit":"0.512","upperLimit":"0.861","value":"0.729"}]}],"title":"6 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.142","upperLimit":"0.575","value":"0.353"},{"groupId":"OG001","lowerLimit":"0.103","upperLimit":"0.551","value":"0.312"},{"groupId":"OG002","lowerLimit":"0.512","upperLimit":"0.861","value":"0.729"}]}],"title":"12 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.095","upperLimit":"0.508","value":"0.283"},{"groupId":"OG001","lowerLimit":"0.103","upperLimit":"0.551","value":"0.312"},{"groupId":"OG002","lowerLimit":"0.425","upperLimit":"0.821","value":"0.663"}]}],"title":"18 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.024","upperLimit":"0.357","value":"0.141"},{"groupId":"OG001","lowerLimit":"0.026","upperLimit":"0.388","value":"0.156"},{"groupId":"OG002","lowerLimit":"0.249","upperLimit":"0.715","value":"0.505"}]}],"title":"24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.024","upperLimit":"0.357","value":"0.141"},{"groupId":"OG001","lowerLimit":"0.005","upperLimit":"0.294","value":"0.078"},{"groupId":"OG002","lowerLimit":"0.176","upperLimit":"0.65","value":"0.421"}]}],"title":"30 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"27"}],"units":"Participants"}],"description":"Kaplan-Meier curves will be used for the time to treatment failure according to the Arm of treatment utilized. Kaplan-Meyer curve analysis was performed to evaluate the time to treatment failure comparison.","dispersionType":"95% Confidence Interval","groups":[{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG000","title":"Arm B (Ixazomib and Dexamethasone)"},{"description":"MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO\n\nLenalidomide: Given PO","id":"OG001","title":"Arm C (Ixazomib, Dexamethasone, Lenalidomide)"},{"description":"UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.\n\nDexamethasone: Given PO\n\nIxazomib: Given PO","id":"OG002","title":"Arm A (Ixazomib and Dexamethasone)"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to 30 months","title":"Time to Treatment Failure","type":"SECONDARY","unitOfMeasure":"Months"}